Do Private Equity and Other Investors Harm Competition in the Pharmaceutical Industry?

Common ownership among rivals and “rollup” deals of smaller pharmaceutical firms by private equity provide strong reasons for antitrust authorities to increase their scrutiny.

https://www.promarket.org/2025/05/15/do-private-equity-and-other-investors-harm-competition-in-the-pharmaceutical-industry/